This updated PocketCard contains the New Medication Class, Dual Incretin Agonist – Tirzepatide (Mounjaro) and includes information on dosing, side effects, and benefits.
We just updated the SGLT-2 considerations section to reflect the 2022 ADA SOC. “Along with metformin, SGLT-2s may be considered at first-line diabetes therapy, especially for those with heart and kidney failure.” We also added, “for renal protection, use SGLT-2 Therapy if eGFR greater than or equal to 25 and UACR greater than or equal to 300.”
Since the GFR cut-offs are changing so frequently for this med class, we took off the GFR guidelines for individual meds and encourage users to review the package insert for the most recent recommendations.
*PocketCardsTM are for individual use only.The updated version with all of these changes will be printed sometime in the third quarter of 2022.
Diabetes Education Services offers education and training to diabetes educators in the areas of both Type 1 and Type 2 Diabetes for the novice to the established professional. Whether you are training to be a Certified Diabetes Care and Education Specialist (CDCES), practicing at an advanced level and interested in board certification, or a health care professional and/or Certified Diabetes Care and Education Specialist (CDCES) who needs continuing education hours to renew your license or CDCES, we have diabetes education information, resources and training; learning and teaching tools; and diabetes online courses available for continuing education (CE). Read our disclaimer for full disclosure.